Evidence map›Paper›PMID 37936467›Full record

ArticleAnti-cancer agents in medicinal chemistry2024

Karanjin, A Promising Bioactive Compound Possessing Anti-cancer Activity against Experimental Model of Non-small Cell Lung Cancer Cells.

Gourav Kumar, Dev Mani Pandey, Manik Ghosh, Stefano Dall'Acqua, Rashmi Gupta, Nishi Prakash Tiwari, Usman Mohd Siddique, Leena Vishwakrama, Sunil Kant Guleri, Uma Ranjan Lal and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Anti-cancer agents in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Gourav KumarDepartment of Bioengineering and Biotechnology, Birla Institute of Technology, Mesra, Ranchi, India.
Dev Mani PandeyDepartment of Bioengineering and Biotechnology, Birla Institute of Technology, Mesra, Ranchi, India.
Manik GhoshDepartment of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, India.
Stefano Dall'AcquaDepartment of Pharmaceutical and Pharmacological Science, University of Padova, Italy.
Rashmi GuptaDepartment of Bioengineering and Biotechnology, Birla Institute of Technology, Mesra, Ranchi, India.
Nishi Prakash TiwariDepartment of Bioengineering and Biotechnology, Birla Institute of Technology, Mesra, Ranchi, India.
Usman Mohd SiddiqueDepartment of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, India.
Leena VishwakramaBirsa Munda Government Medical College, Shahdol, India.
Sunil Kant GuleriBirsa Munda Government Medical College, Shahdol, India.
Uma Ranjan LalDepartment of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, India.
Supriya DubeyDepartment of Chemistry, Kanya Gurukul Campus, Gurukul Kangri (Deemed to be University), Haridwar, India.
Birla Institute of Technology, Mesra · INGovernment Medical College · INGurukul Kangri Vishwavidyalaya · INUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe aim of this study is to isolate the

backgroundIn our earlier research

methodsA novel method was developed through column chromatography for isolation and purification of the compound karanjin from leaf chloroform extract. The purified component was then characterised using FTIR, mass spectrometry, and NMR. An MTT-based cytotoxicity assay was used to analyse cell cytotoxicity, whereas fluorescence staining was used for apoptosis and reactive oxygen species inhibition quantification. Furthermore, the real-time PCR assay was used to determine the molecular mechanism of action in cells causing cytotoxicity induced by karanjin dosing.

resultsThe anticancer activity of karanjin in A549 cell line exhibited prominent activity revealing IC50 value of 4.85 μM. Conferring the predicted molecular pathway study, karanjin restrains the proliferation of cancer cells through apoptosis, which is controlled by extrinsic pathway proteins FAS/FADD/Caspases 8/3/9. Downregulation of KRAS and dependent gene expression also stopped cell proliferation.

conclusionKaranjin has been identified as a compound with potential effect in non-small cell lung cancer cells. Molecular mechanism for apoptosis and inhibition of reactive oxygen species induced through H2O2 were observed, concluding karanjin have medicinal and antioxidant properties.

Indexed as

BenzopyransCarcinoma, Non-Small-Cell LungLung NeoplasmsApoptosisCell Line, TumorHumansHydrogen PeroxideModels, TheoreticalPlant ExtractsReactive Oxygen SpeciesBenzopyransHydrogen PeroxidekaranjinPlant ExtractsReactive Oxygen SpeciesAnticancerApoptosisCharacterizationIsolationKaranjinReactive Oxygen SpeciesROS

Identifiers

PMID37936467
OpenAlexW4388495353

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.